Clinical Trial Detail

NCT ID NCT03214562
Title Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Venetoclax

Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax

Age Groups: senior adult

No variant requirements are available.